In this issue of Clinical Watch, we discuss the evolution of psoriasis treatment. We suggest criteria for a new biologic for plaque psoriasis and review the albumin-lowering effect of dapagliflozin. Finally, we review claims data to identify potential implications of a new psoriasis treatment.
For more information about a specific topic, please contact Janelle Sheen or Karen Powell. Be sure to stay tuned for future monthly updates. For more information about our solutions, please visit conduent.com/pharmacy solutions.